Advanced Applications in Medical Practice 11th International Conference 2022

Regular price
$20.00
Sale price
$20.00
Regular price
$0
Sold out
Unit price
Quantity must be 1 or more

Advanced Applications in Medical Practice 11th International Conference 2022

Format: 8 videos + 1 pdf, size: 28.7 GB

Course Audience: neurologist

Overview:

11th International Conference – Spring 2022

Advanced Applications in Chronic Neurological Disorders

Neurological Autoimmunity

Focus on the more common conditions such as Multiple Sclerosis and Amyotrophic Lateral Sclerosis but also approach the topic so that there is information relevant to any neurological autoimmune process. Diet, Lifestyle and natural interventions will be primarily discussed as will the common uses of drug therapies in neurological autoimmunity. Attention to underlying conditions and comorbidities (infectious, toxic, etc.) will also be a focus.

Addiction

Addiction uses up resources, affects families, and quality of life for many people the world over. Our focus in this area will be on the “top three” areas of medical addiction, Opiates, Alcohol and Benzodiazepines. In addition to standard medical therapies, we will look at integrative support means for addiction medicine to improve patient experiences and treatment outcomes.

Trauma

Brain trauma whether TBI, mTBI or other type is becoming more widely recognized in medical diagnostics and more understood as a pathological entity. Early therapy is obviously best, but we also see many people with late effects of brain trauma that need help. Our focus will be to update the practitioner regarding early diagnosis and intervention where that is appropriate as well as the management of the long-term trauma patient.

Neurotransmitter Balance

As a synergistic intervention to all neurological cases, we will take a specific dive into the use of natural substances and medications to alter and balance neurotransmitters. The way that neurotransmitters are naturally formed and controlled will be related to natural therapies and, where known, appropriate pharmaceuticals and how they intervene in these processes will be discussed.

*Note: these are continuous video recordings during the conference, they include individual lectures mentioned in the Detail section below

Breakout2 (Video MP4 Format)

Breakouts (Video MP4 Format)

May 20 Afternoon Session Neurochemistry; Psychedelic Medicine and Neurotransmission (Video MP4 Format)

May 20 Morning Session Neurochemistry; Neurotransmission and Genomic Influences (Video MP4 Format)

May 21 Afternoon Session Addiction (Video MP4 Format)

May 21 Morning Session Neurological Autoimmunity (Video MP4 Format)

May 22 Afternoon Session Brain Trauma and Healing (Video MP4 Format)

May 22 Morning Session Microdosing Psychedelics (Video MP4 Format)

spring conference 2022 – aampconferences (PDF Format)

* Detail:

May 20

7:45am – Welcome & Introductory Remarks – JEREMY PHILLIPS

Morning Theme: NEUROCHEMISTRY; NEUROTRANSMISSION AND GENOMIC INFLUENCES

8:00am – 9:00am – PAUL ANDERSON, N.M.D.

Neurochemistry – 1 Neurohormonal and Metabolic Factors in Neurology

Hormonal influences on the brain including peripheral and central hormones will be discussed. The effects of corticoids, insulin and other hormones will be detailed as well as the important topic of neurosteroid function and therapies.

9:00am – 10:00am – MARK HEISIG, N.D.

Section #1: Identifying the issues in concussion/PCS (The “5 buckets”)

A very brief look at the neurometabolic cascade and head impact metrics. The 5 Buckets of mTBI: Autonomic, Metabolic, Visual/Vestibular, Cervical, Psychological. Autonomic → Clinical presentation; Orthostatic, HRV, BCTT, Pupillometry testing. Visual/Vestibular → Clinical presentation; VOMS, Simplified notes on detailed pursuit & saccade testing (e.g., intrusions, latency, hypo vs hypermetric). Cervical → Clinical presentation; AROM/PROM, Cervical JPET, SPNTT, Cervical Flexion Rotation testing.

MORNING BREAK: 10:00am – 10:45am

10:45am – 11:45am – PAUL ANDERSON, N.M.D.

Neurochemistry – 2 Neurotransmitters

Primary neurotransmitter biology and therapy will be discussed. Nutrient factors in the synthesis of neurotransmitters and their metabolism will be detailed.

11:45am – 12:30pm – PAUL ANDERSON, N.M.D.

Neurochemistry – 3 Neurological Genomic Factors

Specific neurological pathways, both synthetic and eliminatory, will be discussed in regard to their related SNP areas and their potential for therapies using supportive nutrition.

12:30pm – 1:00pm – BOB MILLER, CTN

How Genetic & Epigenetic Factors Contribute to Depression & Anxiety (non-CME)

How gain of function in iNOS from genetic and environmental factors depletes BH4, the cofactor for creating Serotonin. How mutations in the HEME Cycle contribute to anxiety as GABA receptors are blocked. How upregulation of IL-6 from genetic and environmental factors increases Histamine

LUNCH BREAK: 1:00pm – 2:15pm

Afternoon Theme: NEUROCHEMISTRY; PSYCHEDELIC MEDICINE AND NEUROTRANSMISSION

2:15pm – 3:45pm – ERICA ZELFAND, N.D.

The Science of Psychedelics – How psilocybin, LSD, and other “classic” psychedelics work on the brain

In this module we examine the pharmacology of the “classic psychedelics,” namely psilocybin (the active constituent in “magic mushrooms”) and LSD-25 (also known as “acid”). The effects of these medicines on brain function, chemistry, and neuronal firing will be reviewed, and the concepts of the default mode network (DMN), brain entropy, relaxed belief under psychedelics (REBUS), and child consciousness will be introduced. We will also take a closer look at the role of mystical experiences, and what spirituality has to do with psychological and physiological healing. We will also consider recent clinical studies on using psychedelics for the treatment of nicotine addiction and depression.

3:45pm – 4:15pm – LYLEN FERRIS, N.D.

Evaluating Neurotransmitter Imbalance: An Essential Consideration in the Management of Chronic Disease (non-CME)

How do neurotransmitter imbalances present clinically? Understanding the biochemical pathways and interconnectivity of neurotransmitters is critical before determining clinical applications. This lecture will introduce participants to assessment of neurotransmitters via urinary testing, and help providers begin to employ an integrative approach which has been shown to be more effective in addressing mood disorders, addiction, and more both for the short term and long-term sustained improvement.

AFTERNOON BREAK: 4:15pm – 5:00pm

5:00pm – 6:00pm – PAUL ANDERSON, N.M.D.

Specific Therapeutics in Neurological Healing

Synergy is key in all neurological cases. In this session Dr. Anderson will discuss the common uses of neurofeedback, hyperbaric oxygen, IV and Oral supports and other synergistic therapies.

6:00pm – 6:30pm

EXPERT PANEL DISCUSSION – All Faculty

Neurochemistry; The beginning of Diagnosis and Therapy

Your speakers will use the panel to discuss assessment topics and answer specific questions.

May 21

Morning Theme: NEUROLOGICAL AUTOIMMUNITY

8:15am – 9:15am – KEN SHARLIN, M.D., MPH

Neurological Autoimmunity; Multiple Sclerosis Considerations Part-1

1. Core concepts that define the conventional neurological approach to the patient.

2. How does the conventional neurological approach apply to MS?

3. MS Immunopathology

9:15am – 9:45am – PAUL ANDERSON, N.M.D.

Integrative Considerations in Neurological Autoimmunity

In this session Dr. Anderson will use on of the most difficult types of neurological disease, ALS, to illustrate clinical strategies to address advanced disease

MORNING BREAK: 9:45am – 10:30am

10:30am – 11:30am – KEN SHARLIN, M.D., MPH

Neurological Autoimmunity; Multiple Sclerosis Considerations Part-2

4. An Overview of Conventional Disease-Modifying Therapies for Multiple Sclerosis (including pertinent mechanisms of action)

5. Beyond Conventional Treatment: An Integrative Approach – An Investigation of root causes using the principles of the Functional Medicine Matrix; the Integrative team-based approach to patient management (helping to ensure a path to success); a review of Regenerative Medicine tools in the management of MS.

11:30am – 12:30pm – KEN SHARLIN, M.D., MPH

Neurological Autoimmunity; Multiple Sclerosis Considerations Part-3

6. Considerations for the discontinuation of disease-modifying therapy – patient and practitioner goals and what is known (evidence-based medicine).

12:30pm – 1:00pm – DEIBBY MAMAHIT, M.D.

Managing Neuroinflammation in Autism and Dementia with Antiorbital Ionic Calcium (Non-CME)

Describing the science behind the management of neuroinflammation using AIC, case reports and obtaining patient protocols.

Afternoon Theme: ADDICTION

2:15pm – 3:15pm – AARON VAN GAVER, N.D.

Addiction: Opiate Addiction

In this session Dr. Van Gaver will outline the biological and psychological basis for addiction to opiates. Critical diagnostic features, neurological patterns and other clinical factors will be discussed. Dr. Van Gaver will begin by reviewing the neurobiology of addiction, followed using the DAST-10 and other relevant validated diagnostic scales in order to diagnose opiate addiction.

3:15pm – 3:45pm – JOSEPH DESANTO, M.D.

Implantable Naltrexone in the Use of Weight Loss and Addiction (Non-CME)

How the opioid receptor Antagonist Naltrexone is used in Implantable pellet form to help treat obesity, eating disorders, alcohol and opioid use disorders. Pharmacology, Methodology, Aspects of each Program, and associated Apps will be discussed.

AFTERNOON BREAK: 3:45pm – 4:30pm

4:30pm – 5:30pm – AARON VAN GAVER, N.D.

Addiction: Benzodiazepine Addiction

In this session Dr. Van Gaver will outline the biological and psychological basis for addiction to benzodiazepines. Critical diagnostic features, neurological patterns and other clinical factors will be discussed. Dr. Van Gaver will review the neurobiology of the GABA/Glutamate receptors in the brain, and how benzodiazepines are used in medical practice, followed by their abuse potential. As this is a complex area of addiction, focus will be on how to slowly and safely remove benzodiazepine by supplementing naturopathic treatment options like herbs and orthomolecular vitamins/minerals.

5:30pm – 6:00pm

EXPERT PANEL DISCUSSION – All Faculty

Autoimmunity and Addiction: Clinical Considerations

Your speakers will use the panel to discuss assessment topics and answer specific questions.

May 22

Morning Theme: PSYCHEDELIC INTERVENTIONS AND ADDICTION MEDICINE

8:15am – 9:45am – ERICA ZELFAND, N.D.

Microdosing – What we know (and don’t) about taking miniscule doses of psilocybin and LSD on a regular basis

What happens when we take extremely diluted doses of LSD or psilocybin? Everything or nothing, depending on who you ask. Peppered with cases of people who have tried microdosing, this presentation reviews dosage protocols, critiques the studies currently available on this new way of taking psychedelics, and summarizes their findings. The proposed mechanisms of action of microdosing will be explained, along with safety considerations and drug-drug interactions.

9:45am – 10:45am – AARON VAN GAVER, N.D.

Addiction: Alcohol Addiction

In this session Dr. Van Gaver will outline the biological and psychological basis for addiction to alcohol. Critical diagnostic features, neurological patterns and other clinical factors will be discussed. Dr. Van Gaver will briefly review the neurobiology of the GABA/Glutamate system and how alcohol interacts here. This will be followed by the diagnostic features of alcoholism and the various screening tools used to uncover this in our patients (CAGE, AUDIT). Lastly Dr. Van Gaver will review how to safely guide patients off alcohol use and how to manage withdrawal symptoms such as seizure potential and delirium tremens (DTs).

MORNING BREAK: 10:45am – 11:30am

11:30am – 12:30pm – AARON VAN GAVER, N.D.

Addiction: Case Studies

In this session Dr. Van Gaver will discuss his approach to addiction medicine via a case analysis method. By presenting past patient cases that Dr. Van Gaver has successfully helped manage, he will highlight the steps taken to rehabilitate patients off various substances. Focus will be on naturopathic AND conventional treatment, as well as community-based support groups such as Alcoholics Anonymous and Narcotics Anonymous.

12:30pm – 12:40pm – DR. ANDERSON & JEREMY PHILLIPS

Dr. A. Medical Innovation Awards / AAMP Competition

LUNCH BREAK: 12:40pm – 1:45pm

Afternoon Theme: BRAIN TRAUMA AND HEALING

1:45pm – 2:45pm – MARK HEISIG, N.D.

Section #2: Management of the issues in concussion/PCS

Proposed management algorithm by literature (and CCMI)

1:45pm – 2:45pm – MARK HEISIG, N.D. (Continued)

Case #1 – PCS for 5yrs with suspected CTE by a neurologist. A great well-rounded example of when the algorithm goes well.

Case #2 – Young female with suspected POTS. When everything cleared up except for non-specific cognitive symptoms. Referral to cardiology

Case #3 – Young hockey player with vestibular hypofunction. A tough case with a longer than expected recovery Summary notes on referral network: Exercise Testing, Cervical Spine Manual Therapy → OT, DC, DPT Deficits in pursuits, saccades, NPC, Accommodation → Neuro-optometry. Deficits in VOR, VMS → Vestibular therapy (often DPT or OT). Persistent neurocognitive deficits → Neuropsychology Mental/emotional symptoms/PTSD → CBT/Biofeedback

2:45pm – 3:45pm – MARK HEISIG, N.D.

Section #3: Considerations for athletes & RTP

The purpose of baseline testing is for making return decisions, NOT concussion dx. Incomplete baseline testing: SCAT-5 + ImPACT (or DANA). Complete baseline testing: SCAT-5, ImPACT (or DANA), Rxn Time, Force Plate Balance Baseline testing at rest for RTP decisions is insufficient for returning aerobically trained athletes (e.g., hockey, soccer, lacrosse, rugby, certain football positions, etc…) Return to play programming needs to include dual-tasking & exertion protocol testing. Dual-tasking mirrors the complexities of sport (& evokes persistent deficits in neurocognitive function and gait). Exertion testing prior to RTP baseline testing catches ~1 in 3 athletes that would have been cleared at rest. Matching game-like conditions THEN testing neurocognitive and physical performance provides the safest means for RTP decisions. Return-to-Play Algorithm & Gapski-Goodman Test: Case #4 – Young hockey player injured during summer training camp

3:45pm – 4:30pm – PAUL ANDERSON, N.M.D.

Case Study: Synergistic Therapies in the Traumatized Brain

A recent case detailing the use of therapeutic synergy in healing brain trauma

BRIEF COMFORT BREAK: 4:30pm – 4:40pm

4:40pm – 5:10pm

EXPERT PANEL DISCUSSION – All Faculty

Psychedelic Medicine, Addiction and Trauma

Your speakers will use the panel to discuss assessment topics and answer specific questions.

5:10pm – 5:15pm Closing Remarks & Adjourn

Go to full site